Actinium Pharmaceuticals, Inc. , a leader in the development of differentiated targeted radiotherapies, today announced compelling preclinical data for ATNM-400, a first-in-class Actinium-225 (AC-225) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback